Brought to you by 
Proteon's Series B round brings in $50mm for the company
16 May 2014
Executive Summary
Proteon Therapeutics (developing compounds for cardiovascular and kidney conditions) has raised $38mm through its Series B venture round. Lead investor MPM Capital was joined by fellow backer Vectis Healthcare & Life Sciences Fund and current shareholders TVM Capital, Skyline Ventures, Prism VentureWorks, Intersouth Partners, and several original angel investors. MPM gains representation on Proteon's board. The funds will be used to develop Phase I/II PRT201 to improve the health of chronic hemodialysis patients that undergo arteriovenous fistula surgery. Concurrent with the financing, Proteon announced it had granted Novartis an option to buy the company pending the completion of a Phase II trial of the drug candidate.
Deal Industry
- Pharmaceuticals
-
Biotechnology
- Large Molecule
Deal Status
- Final
Deal Type
-
Financing
- Venture Financing
Already a Biomedtracker subscriber?
You have access to the full deal record through your subscription
Want to become a subscriber?
Subscribers get more deal details, updates, deal financials and deal products.
Questions?
Questions?
Please contact Sales at: (212) 520-2765 or email [email protected]
Related Companies
You must sign in to use this functionality
Authentication.SignIn.HeadSignInHeader
Proteon's Series B round brings in $50mm for the company
Email Deal
All set! This article has been sent to my@email.address.
All fields are required. For multiple recipients, separate email addresses with a semicolon.
DCD.EmailPopout.Notice